Biogen, Alkermes Sue Zydus to Block Copies of Vumerity MS Drug

Biogen Inc. and Alkermes Plc sued Zydus Lifesciences Ltd. on Thursday, alleging that Zydus’ proposed generic version of Vumerity infringes three patents for the multiple sclerosis drug, which last year had more US sales than Biogen’s once-mighty Tecfidera.

The plaintiffs filed their complaint in the US District Court for the District of Delaware. The same patents were at issue in a lawsuit that Biogen and Alkermes filed in March 2021 as they sought to block Teva Pharmaceutical Industries Ltd.’s proposed Vumerity copy. The case was settled that October.

Alkermes Pharma Ireland Ltd. licenses US Patent Nos. 8,669,281; 9,090,558 ...